Pruritus severity as measured by NRS

DUPIXENT® achieved a rapid (as of week 2) and sustained (up to week 16) improvement in pruritus from baseline (secondary endpoint)1

More patients attained ≥4-point improvement in the pruritis NRS scale with DUPIXENT® vs. placebo at week 161

Line graph showing the percentage of patients who achieved a greater than or equal to 4-point improvement in the pruritis NRS in the SOLO 1 trial over time. The x-axis ranges from Week 0 through 16. 224 patients were in the DUPIXENT treatment group and 224 patients were in the placebo group. The percentage of responders in the DUPIXENT group continued to increase through to Week 16. At Week 16, 40.8% of patients in the DUPIXENT group vs. 12.3% in the placebo group were responders. The p value for this comparison is less than 0.0001.

Adapted from the Product Monograph.1

A significantly greater proportion of patients randomized to DUPIXENT® achieved a rapid improvement in the pruritus NRS compared to placebo (defined as >4-point improvement as early as week 2; p<0.01) and the proportion of patients responding on the pruritus NRS continued to increase through the treatment period.1


*p<0.01 versus placebo
** p<0.0001 versus placebo
† In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing
data were considered non-responders. Full Analysis Set (FAS) includes all subjects randomized.

DUPIXENT® achieved a rapid (as of week 2) improvement in pruritus from baseline and improvement was observed at week 52 (secondary endpoint)

More patients attained ≥4-point improvement in the pruritis NRS scale with DUPIXENT® vs. placebo at week 161

Line graph showing the percentage of patients who achieved a greater than or equal to 4-point improvement in the pruritis NRS in the SOLO 2 trial over time. The x-axis ranges from Week 0 through 16. 223 patients were in the DUPIXENT treatment group and 236 patients were in the placebo group. The percentage of responders in the DUPIXENT group continued to increase through to Week 16. At Week 16, 36% of patients in the DUPIXENT group vs. 9.5% in the placebo group were responders. The p value for this comparison is less than 0.0001.

Adapted from the Product Monograph.1

A significantly greater proportion of patients randomized to DUPIXENT® achieved a rapid improvement in the pruritus NRS compared to placebo (defined as >4-point improvement as early as week 2; p<0.01) and the proportion of patients responding on the pruritus NRS continued to increase through the treatment period.1


*p<0.01 versus placebo
** p<0.0001 versus placebo
† In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing
data were considered non-responders. Full Analysis Set (FAS) includes all subjects randomized.

DUPIXENT® achieved a rapid (as of week 2) and sustained (up to week 16) improvement in pruritus from baseline (secondary endpoint)1

Line graph showing the percentage of patients who achieved a greater than or equal to 4-point improvement in the pruritis NRS in the CHRONOS trial over time. The x-axis ranges from Week 0 through 52. 106 patients were in the DUPIXENT treatment group and 315 patients were in the placebo group. At Week 52, 51% of patients in the DUPIXENT plus TCS group vs. 13% in the placebo plus TCS group were responders. The p value for this comparison is less than 0.0001.

Adapted from Blauvelt A, et al., and the Product Monograph.1

A significantly greater proportion of patients randomized to DUPIXENT® demonstrated a >4-point improvement in peak pruritus NRS compared to placebo at weeks 2, 4, 16, 24 and 52.1,5


¥ p=0.0062 versus placebo
* p<0.0001 versus placebo
Full Analysis Set (FAS) includes all subjects randomized.
‡ All patients were on background TCS therapy and patients were permitted to use topical calcineurin inhibitors.

Pruritus Numerical Rating Scale (NRS)

The Pruritus NRS is a patient-reported measure that assesses the average itch intensity over a 24-hour period using a 0-to-10-point scale. A variation of this scale measures maximum itch intensity and is referred to as peak pruritis NRS (PP-NRS). Patients are asked to assign a number reflecting their itch intensity on a numerical rating scale like the one below. The Pruritis NRS takes about 1 minute to complete.7,11

“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”

 

Scale ranging from 0 to 10 showing how itch is rated on the Pruritus NRS. Aero indicates no itch, and 10 indicates the worst itch imaginable.
A reduction in itch as defined by at least a 4-point improvement in the peak pruritus NRS from baseline to Week 16.1

Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.
 

START NOW

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.
 

REQUEST A VISIT
Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo

Contact Us
Terms & Conditions
Privacy Policy
Cookie Policy
Site Map

DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo